Vimarsana
Biggest News Aggregation in the World

Page 3 - Mark Corbae News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Corbae. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Corbae Today - Breaking & Trending Today

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board - Vimarsana News

Phosplatin Therapeutics Appoints Lorenzo Galluzzi, PhD, a Pioneer in Immunogenic Cell Death Research, to Scientific Advisory Board

/PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of...

Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma - Vimarsana News

Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma

/PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics,...

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC) - Vimarsana News

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC) - Vimarsana News

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC) - Vimarsana News

Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)

Phase I clinical trial expected to initiate in second quarter 2022 HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the "safe to proceed" letter from the U.S. Food and Drug Administration (FDA) for the Company's...